Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. held its 2022 Annual Meeting on May 31, with 49.2% of shares represented. Key voting results included:
- Chris Bunka elected with 97.15% approval
- John Docherty elected with 87.25% approval
- Nicholas Baxter elected with 84.5% approval
- Ted McKechnie elected with 96.1% approval
- Albert Reese Jr. elected with 96.56% approval
- Davidson & Company LLP appointed as auditors with 98.77% approval
- Non-binding compensation approval for executives at 93.52%
- Directors' past actions ratified at 91.1%
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the receipt of its 25th patent for its DehydraTECH technology, specifically aimed at enhancing the delivery of antiviral drugs. The patent, No. 11,311,559, will be issued on April 26, 2022, validating the effectiveness of DehydraTECH in improving bioavailability. Studies show that antiviral drugs processed with this technology achieve peak blood concentrations double that of standard drugs. This patent reinforces Lexaria's commitment to innovation in drug delivery and enhances its patent portfolio across various countries.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has initiated a multi-week human clinical study, HYPER-H21-4, aimed at evaluating the effectiveness of DehydraTECH-CBD for reducing blood pressure and other clinical benefits. This randomized, double-blind study involves 60 participants and is designed to bolster Lexaria's chances for an Investigational New Drug application with the FDA. Preliminary results show no serious adverse events, indicating good tolerance of DehydraTECH-CBD. The hypertension market, valued at $28 billion, presents a significant opportunity for Lexaria's innovative treatment.
Lexaria Bioscience Corp. announced positive results from its pulmonary hypertension clinical study, HYPER-H21-3, showing DehydraTECH-CBD significantly reduced pulmonary artery systolic pressure (PASP) in male participants. The treatment demonstrated a 41% overall reduction in PASP (p=0.045) during hypoxic conditions, supporting further research efforts. Lexaria intends to utilize these findings to seek FDA approval for formal clinical testing in hypertension management. The global hypertension market, valued at $28 billion, presents a significant opportunity for DehydraTECH-CBD as a potential treatment option.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a new human nicotine study, NIC-H22-1, set to commence this summer, involving a minimum of 36 participants. The double-blinded study aims to compare the performance of Lexaria's DehydraTECH-nicotine pouches against leading brands like ON! and Zyn, with a focus on pharmacokinetic data and subjective user experiences. Lexaria previously noted success in animal studies, showing a significant increase in nicotine absorption speed. The oral nicotine pouch market is projected to grow significantly, reaching $21.84 billion by 2027.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has launched its epilepsy research program, EPIL-A21-1, which will evaluate the effectiveness of DehydraTECH-CBD against Epidiolex, the first FDA-approved CBD treatment for seizures. The necessary test articles have been prepared and delivered to a third-party lab for dosing. Research phases will include acute and chronic seizure models, starting in May/June, with results expected by Q3 2022. The program is fully funded through existing resources, underscoring Lexaria's commitment to advancing its drug delivery technology.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the granting of its 24th patent, titled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof," enhancing its global intellectual property portfolio. This Australian patent allows the use of DehydraTECH technology for various nicotine forms, potentially increasing product value. Previous studies show DehydraTECH delivers nicotine significantly faster than conventional methods. Additionally, the company issued 36,700 stock options to staff at an exercise price of $3.39.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reported significant findings from an animal study evaluating its DehydraTECH formulation of sildenafil, showing a 74% increase in drug delivery at 4 minutes compared to a generic control. The study indicated a 70% higher maximum concentration (Cmax) and a 37% improvement in total delivery (AUC). Results showed potential for developing faster-acting sildenafil formulations. However, improvements did not achieve statistical significance, necessitating further studies.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) shared an annual letter from CEO Chris Bunka, highlighting successes and strategic directions for the company. The focus remains on advancing the DehydraTECH drug delivery technology, aimed at overcoming industry inertia and regulatory challenges. Lexaria reported a growth in shareholder base, with average shares owned by NOBO shareholders increasing by 216% in 2021. The company's institutional ownership has also surged, ranging between 9% and 16%. The aim is to leverage this momentum for potential regulatory and commercial success in 2022.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
